US ITC Ruling and Apple Circumvention Strategy for Feature Restoration

Apple has led the wearable healthcare market by introducing blood oxygen monitoring (Blood Oxygen Monitoring) to Apple Watch over recent years. However, medical device company Masimo filed suit claiming Apple infringed its patented technology. Core issue: non-invasive blood analysis technology. Masimo 502 and 648 patents: using LED to shine light on body tissue (such as the wrist), analyzing the wavelength of light reflected and transmitted through a photodiode to measure blood oxygen saturation (SpO2) -- tracking the "attenuated wavelength" (light absorbed by oxygen molecules) to estimate oxygen levels. The ITC (US International Trade Commission) in late 2023 determined Apple infringed portions of Masimo 502 and 648 patents and issued a Limited Exclusion Order (LEO) -- certain Apple Watch models became unable to activate blood oxygen functionality in the US. Legal proceedings: Masimo filed the original patent complaint (August 2021); ITC initial determination (October 2023) finding infringement; USITC formal ruling (November 2023) upholding infringement; US Customs and Border Protection enforcement beginning; Apple appealed to the Court of Appeals for the Federal Circuit. Apple circumvention strategy: rather than waiting for appeal resolution, Apple modified the blood oxygen sensor algorithm to avoid the specific patent claims while maintaining some measurement functionality -- a software-based workaround that changes how the sensor operates to fall outside the patent claims while preserving partial SpO2 capability. The broader IP implications: the Apple-Masimo dispute illustrates the patent thicket problem in wearable health technology where fundamental measurement methodologies are covered by existing medical device patents -- consumer electronics companies entering health monitoring face significant IP exposure from established medical device industry patent portfolios.